Burosumab therapy in children with X-linked hypophosphatemia

New England Journal of Medicine

Volumn 378, Issue 21, 2018, Pages 1987-1998

  Carpenter, Thomas O ^a   Whyte, Michael P ^b   Imel, Erik A ^c   Boot, Annemieke M ^d   Högler, Wolfgang ^e   Linglart, Agnès ^h   Padidela, Raja ^f   Van't Hoff, William ^g   Mao, Meng ⁱ   Chen, Chao Yin ⁱ   Skrinar, Alison ⁱ   Kakkis, Emil ⁱ   Martin, Javier San ⁱ   Portale, Anthony A ^j  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^f ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ ULTRAGENYX PHARMACEUTICAL INC   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BUROSUMAB; FIBROBLAST GROWTH FACTOR 23; PHOSPHORUS; FIBROBLAST GROWTH FACTOR;

ABDOMINAL PAIN; ADVERSE EVENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BODY WEIGHT; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; INCIDENCE; INJECTION SITE REACTION; KIDNEY TUBULE ABSORPTION; MALE; NAUSEA; NOSE OBSTRUCTION; OROPHARYNX PAIN; OVERALL SURVIVAL; PAIN; PAIN SEVERITY; PATIENT-REPORTED OUTCOME; PHARMACODYNAMIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PHYSICAL CAPACITY; POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; RHINORRHEA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; X LINKED HYPOPHOSPHATEMIC RICKETS; ANALGESIA; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFECT; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GROWTH; KIDNEY TUBULE; KNEE; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; X CHROMOSOME LINKED DISORDER;

ALKALINE PHOSPHATASE; CHILD; CHILD, PRESCHOOL; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FIBROBLAST GROWTH FACTORS; GENETIC DISEASES, X-LINKED; GROWTH; HUMANS; KIDNEY TUBULES; KNEE JOINT; MALE; PAIN MANAGEMENT; PHOSPHORUS; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX;

EID: 85047731982     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1714641     Document Type: Article

References (38)

1. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 2011; 26: 1381-8.
2. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18: 1637-47.
3. Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore) 1989; 68: 336-52.
4. Lee JY, Imel EA. The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev 2013; 10: Suppl 2: 367-79.
5. Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 2014; 3: R13-R30.
6. Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 1980; 303: 1023-31.
7. Petersen DJ, Boniface AM, Schranck FW, Rupich RC, Whyte MP. X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy. J Bone Miner Res 1992; 7: 583-97.
8. Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003; 88: 3591-7.
9. Nielsen LH, Rahbek ET, Beck-Nielsen SS, Christesen HT. Treatment of hypophosphataemic rickets in children remains a challenge. Dan Med J 2014; 61: A4874.
10. Rafaelsen S, Johansson S, Rader H, Bjerknes R. Hereditary hypophosphatemia in Norway: a retrospective populationbased study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 2016; 174: 125-36.
11. Santos F, Fuente R, Mejia N, Mantecon L, Gil-Pena H, Ordonez FA. Hypophosphatemia and growth. Pediatr Nephrol 2013; 28: 595-603.
12. Zivicnjak M, Schnabel D, Billing H, et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 2011; 26: 223-31.
13. Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 2014; 124: 1587-97.
14. Imel EA, Zhang X, Ruppe MD, et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 2015; 100: 2565-73.
15. Ruppe M, Peacock M, Weber T, et al. Clinical and radiographic characteristics of adult X-linked hypophosphatemia (XLH) in a cohort of patients treated with KRN23, an antibody to FGF23. Presented at the ASBMR 2016 Annual Meeting, Atlanta, September 16-19, 2016: MO0319. abstract.
16. Endo I, Fukumoto S, Ozono K, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 2015; 62: 811-6.
17. Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 2008; 42: 1235-9.
18. Thacher TD, Fischer PR, Pettifor JM, Lawson JO, Manaster BJ, Reading JC. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr 2000; 46: 132-9.
19. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991; 325: 1843-8.
20. Whyte MP, Fujita KP, Moseley S, Thompson DD, McAlister WH. Validation of a novel scoring system for changes in skeletal manifestations of hypophosphatasia in newborns, infants, and children: the Radiographic Global Impression of Change scale. J Bone Miner Res 2018;33: 868-74.
21. Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM. Rickets. Nat Rev Dis Primers 2017; 3: 17101.
22. Chesney RW, Rosen JF, Hamstra AJ, DeLuca HF. Serum 1, 25-dihydroxyvitamin D levels in normal children and in vitamin D disorders. Am J Dis Child 1980; 134: 135-9.
23. Kruse K, Kracht U, Gopfert G. Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 1982; 57: 217-23.
24. Lockitch G, Halstead AC, Albersheim S, MacCallum C, Quigley G. Age- and sexspecific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin Chem 1988; 34: 1622-5.
25. Daltroy LH, Liang MH, Fossel AH, Goldberg MJ. The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. J Pediatr Orthop 1998; 18: 561-71.
26. Flegal KM, Cole TJ. Construction of LMS parameters for the Centers for Disease Control and Prevention 2000 growth charts. Natl Health Stat Report 2013; 11: 1-3.
27. Geiger R, Strasak A, Treml B, et al. Six-minute walk test in children and adolescents. J Pediatr 2007; 150: 395-9.
28. Klepper SE. Measures of pediatric function: Child Health Assessment Questionnaire (C-HAQ), Juvenile Arthritis Functional Assessment Scale (JAFAS), Pediatric Outcomes Data Collection Instrument (PODCI), and Activities Scale for Kids (ASK). Arthritis Care Res (Hoboken) 2011; 63: Suppl 11: S371-S382.
29. Patriquin H, Robitaille P. Renal calcium deposition in children: sonographic demonstration of the Anderson-Carr progression. AJR Am J Roentgenol 1986; 146: 1253-6.
30. Sabbagh Y, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A 2005; 102: 9637-42.
31. Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 2009; 24: 1879-88.
32. Aono Y, Hasegawa H, Yamazaki Y, et al. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res 2011; 26: 803-10.
33. Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998; 139: 4391-6.
34. Morrell DC. Symptom interpretation in general practice. J R Coll Gen Pract 1972; 22: 297-309.
35. Hay AD, Heron J, Ness A. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. Fam Pract 2005; 22: 367-74.
36. Antonaci F, Voiticovschi-Iosob C, Di Stefano AL, Galli F, Ozge A, Balottin U. The evolution of headache from childhood to adulthood: a review of the literature. J Headache Pain 2014; 15: 15.
37. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol 2010; 52: 1088-97.
38. Clifford RD, Radford M, Howell JB, Holgate ST. Prevalence of respiratory symptoms among 7 and 11 year old schoolchildren and association with asthma. Arch Dis Child 1989; 64: 1118-25.